| HS Code | 372319 |
| Product Name | AnaGF® Fibronectin |
| Form | Lyophilized powder |
| Source | Human plasma |
| Purity | ≥95% (SDS-PAGE) |
| Application | Cell culture coating |
| Endotoxin Level | <1 EU/mg |
| Storage Temperature | -20°C |
| Reconstitution Buffer | Sterile water or PBS |
| Molecular Weight | 440 kDa (dimer) |
| Sterility | Sterile-filtered |
| Catalog Number | AG853 |
| Package Size | 500 μg |
| Shelf Life | 2 years from manufacturing date |
| Usage | For research use only |
| Species | Human |
As an accredited AnaGF® Fibronectin factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | AnaGF® Fibronectin is supplied in a 1 mg sterile, lyophilized vial with a secure screw cap, labeled for laboratory use. |
| Shipping | AnaGF® Fibronectin is shipped under refrigerated conditions (2–8°C) to ensure product stability and integrity. It is securely packed with ice packs in insulated containers to maintain the required temperature during transit. Immediate storage at recommended conditions upon arrival is essential for optimal performance and shelf life. |
| Storage | AnaGF® Fibronectin should be stored at -20°C in a tightly sealed container to maintain stability and prevent contamination. Avoid repeated freeze-thaw cycles; aliquot the protein if necessary. Protect from light and moisture. Upon thawing, keep the product on ice and use within a short period for best results. Follow manufacturer instructions for optimal storage and handling. |
AnaGF® Fibronectin supports critical process performance in advanced cell culture, regenerative medicine, biomedical research, and tissue engineering sectors. As a specialized extracellular matrix protein, it plays a key role as a cell attachment factor and biological substrate. We supply consistent, high-purity fibronectin to meet industrial-scale formulation and downstream process integration requirements.
Large-volume producers of biopharmaceuticals and vaccines require fibronectin as an essential substrate for anchorage-dependent cell line expansion. Our material helps manufacturers improve cell yield and viability in serum-free and reduced-serum protocols. Production-scale users prioritize lot-to-lot performance consistency, traceability, and regulatory documentation. Fibronectin enters the workflow at the vessel coating or microcarrier preparation stage, with validated surface density to support high-density adherent cultures. Industrial customers adjust concentration based on cell type sensitivity, vessel type, and batch process kinetics.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Manufacturers of tissue scaffolds and implantable biomaterials rely on fibronectin to enhance cell seeding, proliferation, and integration into biopolymer constructs. Integration concentrates on polylactic acid, polyglycolic acid, collagen, and hydrogel scaffolds engineered for orthopedics, wound healing, and reconstructive applications. Fibronectin forms a critical interface for cellular interaction, facilitating regulatory approval for advanced medical devices. Direct addition usually occurs during final surface functionalization of prefabricated scaffolds within controlled cleanroom manufacturing lines.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Diagnostic reagent and kit manufacturers use fibronectin for microplate surface coating, enabling high-sensitivity adhesion assays and cell-based diagnostic formats. This application demands rigorous quality documentation, leachables control, and validation flexibility across a range of proprietary ELISA and cell-adhesive bioassays. The protein is introduced at controlled concentrations during automated microplate processing, with pre- and post-coat wash steps monitored under routine GMP batch records.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Industrial suppliers of bio-inks add fibronectin to printable hydrogels and polymer blends, supporting cell adhesion and tissue structure fidelity in bioprinted constructs. The protein is included at precise concentrations to balance rheology, printability, and in situ bioactivity. The ingredient enters during compounding under aseptic, GMP-equivalent conditions, with defined ratio-to-polymer requirements for customer-specific bio-ink recipes. Batch records must reflect biological source, purity, and traceability in clinical and preclinical bioprinting workflows.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Producers of research-use-only (RUO) assay kits for autoimmune disease studies incorporate fibronectin as a substrate for cell adhesion, migration, and signal transduction investigations. The application requires high protein purity and batch documentation supporting downstream cell-based screening. Usage focuses on assay plates, membrane supports, and microfluidic devices designed for preclinical research and pharma screening pipelines. Fibronectin is introduced pre-assembly at validated points to guarantee assay reproducibility and cell-function reliability.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive AnaGF® Fibronectin prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618136850665 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8618136850665
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
AnaGF® Fibronectin comes from years of focused development in recombinant protein technology. Our team understands that the protein source determines reliability in cell culture outcomes. Every vial of AnaGF® Fibronectin is produced in our dedicated sterile facilities using a recombinant process in E. coli, rebuilt from the full-length human gene. This means that the fibronectin you receive matches native human sequences as closely as possible. We take a hands-on approach to media optimization, fermentation, and purification, closely monitoring critical parameters because minor shifts can influence cell attachment and signal transduction in sensitive assays.
Research groups tend to encounter frustrating inconsistencies with plasma-derived fibronectin. Donor-to-donor variability, undefined plasma factors, and unpredictable performance in stem cell and primary cell cultures become a bottleneck for reproducibility. The biggest concern we hear from collaborators centers on batch-to-batch differences that disrupt cell morphology or adhesion. Our recombinant production eliminates this unpredictability. Each lot is strictly controlled for purity, molecular integrity, and biological activity, so cells show consistent behavior across experiments. We test every batch using cell adhesion assays on sensitive human iPSC and mesenchymal stem cells, confirming that each vial gives results equivalent to the last.
The AnaGF® Fibronectin portfolio starts with model AFN-100, supplied as a lyophilized powder at 1 mg per vial, and AFN-500, which delivers 5 mg in the same format. Both models are solubilized easily in sterile water or PBS. Purity consistently exceeds 97% as measured by SDS-PAGE and HPLC; these standards are set based on over 1000 lots produced in our facilities. Endotoxin levels mean more to us than just a marketing number; we process every batch through a proprietary multi-step removal pipeline and routinely achieve less than 0.05 EU/µg, verified on Limulus Amebocyte Lysate testing. Stringent DNase/RNase and protease testing avoids surprise degradation during long-term usage.
Protein sequences and confirmatory mass spectrometry are available for every batch. The final freeze-drying step locks in long-term stability; we store our inventory under nitrogen, a practice developed after early spoilage issues forced us to rethink storage. Field data shows preserved adhesion activity for up to 18 months at -80°C, giving laboratories a reliable window to use material.
Growth of human iPSCs, hESCs, neural progenitors, primary airway cells, and tumor spheroids presents very different substrates and signaling environments. Researchers have used AnaGF® Fibronectin coated on tissue culture plastic, glass slides, microfluidic chips, and organ-on-chip devices. Surface coating with AnaGF® supports single-cell passaging, clonal expansion, and late-stage differentiation. One team reported improved cardiomyocyte beating on our protein, noting higher attachment rates over commercial plasma fibronectin. Our labs have replicated this with routine immunostaining for α-actinin and Vimentin, documenting robust spreading that aligns with leading published protocols.
Coating concentrations are not a guess; recommended dosages are based on in-house titration studies with automated cell counters and live imaging. We have documented cell attachment efficiency at 0.5–10 µg/cm², and routinely help clients balance performance against cost per square centimeter. Our protein integrates well with other ECM components, including vitronectin, laminin, and collagens. Numerous stem cell core facilities now use our product in combination protocols to drive organoid formation and directed differentiation in chemically defined conditions.
Plasma or animal-derived fibronectin can introduce complex variables—residual growth factors, immunoglobulins, viruses, or degradation fragments are just a few examples. We transitioned to recombinant-only production after sustained requests from cell therapy and cell banking clients that needed documentation on origin, sequence, and sterility. AnaGF® Fibronectin is xeno-free, making it suitable for clinical research and cGMP environments. Every step, from bacterial strain banking to chromatography, is tracked by electronic batch records and monitored by trained technical staff; we invite visiting QA teams to walk through the process so they know exactly how their material gets made.
Manufacturers that rebrand or repack source material cannot offer full transparency on source strains, vectors, or upstream bioprocessing choices. We design every vector in-house, monitor fermentation through real-time analytics, and tag each protein batch with traceable lot codes. By maintaining complete control from gene to vial, we respond rapidly to feedback. For instance, an early feedback loop from a regenerative medicine group led us to invest in a new anion exchange step, improving our removal of host-cell proteins below detectable limits. We also reject material that drifts from the correct isoelectric profile or exhibits increased proteolytic fragments, based on direct feedback from image-based validation studies and not just paperwork.
Competitor products may rely on animal components or blended formats that mask lot-to-lot or year-to-year shifts—this can derail sensitive cell culture projects without warning. Our clients trust us because we share full analytical profiles, including SEC-MALS, endotoxin results, and bioactivity alongside every shipment.
Over time, we have partnered with groups involved in gene-editing, bioprinting, and microphysiological system development. Their protocols often push the boundaries of what ECM substrates can tolerate, demanding both higher concentrations and lower impurity levels. We have developed larger-scale cGMP-packaged lots, double-filtered for sterility after lyophilization, and compatible with bespoke surface chemistries or PEGylation needs. A research hospital group requested custom packaging to support GMP cell expansion, and our team developed a process for filling under nitrogen in vials with tamper-resistant seals, combining utility with ease of traceability.
These requests help drive our process evolution. We maintain an open line with our most advanced users: when a cell bank encountered clumping and spontaneous aggregation with plasma fibronectin sources, we helped them run side-by-side protocols using AnaGF® Fibronectin. They reported dramatically reduced cluster formation and improved clonal outgrowth in feeder-free conditions. Our response time – from request to shipped solution – is tight because the entire protein chain resides under our roof.
Our team documents the entire upstream and downstream process for every batch. These records satisfy institutional review committees, regulatory audits, and supply chain traceability checks. We openly share Certificates of Analysis, density and concentration measurements, endotoxin and host-cell protein profiles, and even amino acid composition on request. Auditors from multiple agencies have reviewed our batch records and praised the clarity of source material documentation.
As part of our regulatory support, AnaGF® Fibronectin batches can be purchased with additional QC panels—virus and mycoplasma testing, 0.2 µm post-fill filtration documentation, and identity confirmation by immunoblotting or sequencing. This level of documentation has helped leading cell therapy manufacturers standardize their protocols for preclinical runs and early IND submissions. We regularly work under CDA with academic and industry partners to adapt documentation or supply specialized lot history for custom studies.
A biomanufacturing group focusing on induced pluripotent stem cell therapies faced repeated failures in scaling up their cultures. They traced issues to surface coating inconsistency with plasma-derived fibronectin—high lot-to-lot variability drove erratic cell attachment rates and forced them to retool their entire expansion process. After switching to AnaGF® Fibronectin, their reports showed robust cell morphology and a four-fold improvement in expansion consistency over six months. Sequencing and imaging confirmed stable gene expression and reduced differentiation drift, supporting them in moving several batches toward clinical-grade manufacturing.
Their story is familiar. Organizations that invest millions in manufacturing platforms rely on predictability. In our experience, even a minor shift in coating or protein quality ripples through a process, driving extra QA and delaying releases. Recombinant fibronectin with traceable provenance and clean documentation tightens up these variables, bringing peace of mind to quality managers and real savings for process engineers.
As the original producer, we go beyond transactional supply. Our scientists review emerging literature and collaborate on technical development, continuously evolving protein design and purification as new needs emerge. Recent industry trends toward defined, xeno-free culture make traceable solutions essential—not just for academic labs but also for cell therapy and bioprocessing firms. We invite direct collaboration and committee-level discussions when clients need lot selection, protocol optimization, or extended validation.
We stay engaged with scientific conferences, user group meetings, and standards organizations, not just to promote AnaGF® Fibronectin, but to keep pace with evolving protocols and regulatory expectations. User feedback fuels our protein development and process improvements. Only through sustained, end-to-end production control and direct relationships with real laboratories can a manufacturer anticipate the challenges of advanced cell culture work.
Our innovation does not pause. We currently investigate novel bioengineering strategies for AnaGF® Fibronectin variants with domain deletions, site-specific tags, or chemical conjugation potential. The goal is to help leading groups push their science further without adding risk from uncertain supply chains or ambiguous protein chemistry. This includes surface-active forms for microcarrier culture, dual-function constructs with growth factor binding sites, and scalable production formats that match GMP and clinical trial needs.
Championing the adoption of defined, animal-free extracellular matrix proteins strengthens the entire field, from single academic projects to global manufacturing partnerships. With every new batch, we reaffirm our commitment to reliability, transparency, and data-driven evolution—rock-solid foundations for the next decade of cellular medicine.
Choosing AnaGF® Fibronectin means working with a dedicated team that understands the stakes in cell research and manufacturing. Our recombinant approach, direct production control, and open channels for documentation and feedback set us apart. Through our continuous product evolution, hands-on partnership, and unwavering attention to quality, AnaGF® Fibronectin redefines the standard for fibronectin in advanced cell systems.
